06/09/2017 “Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
06/09/2017 “L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
06/09/2017 “BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
06/07/2017 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/06/2017 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/01/2017 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Icon check
06/01/2017 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Icon check
05/30/2017 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Icon check
05/30/2017 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Icon check
05/19/2017 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Icon check
05/15/2017 Number of shares and voting rights of ADOCIA as of April 30, 2017 Icon check
04/18/2017 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Icon check
04/18/2017 Adocia announces first quarter 2017 financial results Icon check
04/13/2017 Number of shares and voting rights of Adocia as of March 31, 2017 Icon check
03/13/2017 Number of shares and voting rights of ADOCIA as of February 28, 2017 Icon check
03/07/2017 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Icon check
02/14/2017 Adocia announces its revenue and cash position for 2016 Icon check
02/13/2017 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Icon check
01/27/2017 Adocia to hold conference call on Monday January 30, 2017 Icon check
01/27/2017 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Icon check
01/25/2017 Adocia to hold conference call providing an update on its programs Icon check
01/19/2017 Adocia announces the transformation of its business model to increase the value of its projects Icon check
01/06/2017 Half year report on Adocia’s liquidity agreement with Kepler Chevreux
01/05/2017 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Icon check
01/04/2017 Adocia announces its financial calendar for 2017 Icon check
12/16/2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Icon check
11/10/2016 Adocia to Participate in Upcoming Investor Conferences Icon check
11/07/2016 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Icon check
10/27/2016 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
10/12/2016 Adocia announces third quarter 2016 financial results Icon check
09/22/2016 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Icon check
09/20/2016 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Icon check
09/19/2016 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Icon check
09/15/2016 BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/15/2016 “BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/08/2016 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Icon check
09/07/2016 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Icon check
08/25/2016 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Icon check
07/20/2016 Adocia presents first half 2016 financial results Icon check
07/05/2016 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
06/11/2016 “A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
06/10/2016 “Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2016 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Icon check
06/06/2016 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Icon check
06/02/2016 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Icon check
05/31/2016 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
05/13/2016 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Icon check
05/03/2016 Adocia strengthens its BioChaperone Combo patent portfolio Icon check
04/27/2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Icon check
04/14/2016 Adocia announces first quarter 2016 results Icon check
Join our mailing list. Subscribe